CJC-1295 No DAC Research: Fasting Considerations

In published research on growth-hormone-axis signaling, feeding state is a controlled variable in the study design — never an instruction to a person. CJC-1295 without DAC is a research-use-only GHRH analog, and because nutrient-related signals such as circulating glucose, free fatty acids, and somatostatin tone appear to modulate GH-axis activity, investigators commonly standardize fasted or fed conditions across subjects and model systems so that the signal they measure isn't buried in metabolic noise. That is the honest, complete scope of what a supplier or reseller can say about the subject.

The practical question for a business buyer is narrower and more useful: if feeding state is one variable in a study, the compound itself shouldn't be another. Purity, peptide content, salt form, and lot-to-lot consistency all determine whether a research customer can attribute a result to the compound or to your vial. That is what your sourcing decision actually controls.

Why feeding state shows up as a variable in GH-axis models

Growth hormone release is pulsatile and tightly regulated by opposing inputs — growth-hormone-releasing hormone on one side, somatostatin on the other. Decades of endocrinology research indicate that metabolic state influences that balance: studies suggest elevated circulating glucose tends to blunt GHRH-stimulated GH release in model systems, while fasted conditions are generally associated with larger, more frequent pulses. Free fatty acid availability has also been implicated as a modulating input.

For a researcher, that creates an obvious methodological problem. If half the subjects in a model are in a post-absorptive state and half are not, baseline variability can swamp whatever effect the compound is being studied for. The standard response is to standardize: same interval since last feeding, same light cycle, same sampling windows. Fasting in that context isn't an intervention — it's an attempt to make measurements comparable.

This matters to you commercially because it explains the shape of the questions your customers will ask. They won't ask what to do; they'll ask what's known, and whether your product documentation is detailed enough to hold up in a study record. A buyer who understands that distinction writes better catalog copy and stays much further away from regulatory trouble than one who doesn't.

What removing the DAC changes about experimental timing

The DAC in CJC-1295 stands for Drug Affinity Complex — a moiety that binds serum albumin and dramatically extends circulating half-life. Strip it out, and you have a short-acting GHRH analog whose activity profile is measured in minutes rather than days. That single structural difference is why the two forms are not interchangeable in study design and why they are catalogued separately.

The short half-life is precisely why timing-related variables, including feeding state, get more attention in research using the no-DAC form. With a long-acting analog, exposure is relatively continuous and a single meal is a smaller perturbation. With a short-acting analog, the metabolic conditions at the moment of the experiment carry more weight, so investigators tend to specify them tightly in their methods.

None of that translates into guidance for a human being, and your product pages should never let a reader think it does. The research-use-only framing exists exactly here: describing what investigators control in a laboratory is legitimate; converting it into a schedule, a window, or a suggestion is not.

The naming problem that costs resellers credibility

CJC-1295 without DAC is frequently listed elsewhere as Mod GRF (1-29), Modified GRF, or CJC-1295 DAC-free, and some sellers blur it into the DAC version entirely. For a research customer comparing vials across suppliers, that ambiguity is disqualifying — they cannot cite a compound they cannot identify.

If you're building a catalog, decide on one canonical name per SKU, state the sequence modification plainly, and make the presence or absence of DAC unmissable in the title rather than in fine print. Then make sure the certificate of analysis you hand over actually corresponds to the lot in the customer's hand. Suppliers who publish a single generic COA for a compound rather than per-batch results are, functionally, asking your customer to take identity on faith. Real Peptides lists CJC-1295 No DAC 10mg as its own catalog item with batch-specific documentation for exactly that reason.

What to verify before you stock any GHRH analog

This is the part of the decision that is entirely within your control. Before you commit to a supplier — any supplier — work through the following and get answers in writing.

Two industry practices deserve a hard no. First, COAs available only on request or behind a paywall — if test data is a sales concession rather than a published record, it isn't verification. Second, hidden wholesale pricing that requires a sales call before you can see a single number; you cannot model a catalog around a quote you have to negotiate for every time.

Where fasted-state questions become a compliance problem

Here is the trap. A customer emails asking whether to run fasted. It feels helpful to answer. The moment you do, your business has moved from selling a research chemical to advising on use in a person — and that shift is visible to regulators, payment processors, and plaintiff's attorneys alike.

The durable approach is to keep every public-facing statement about the compound descriptive and literature-anchored, decline use questions as a matter of policy, and let your labelling carry the research-use-only designation consistently across vials, invoices, and web copy. Peptides sold this way are not FDA-approved drugs and are not for human consumption; nothing in your marketing should invite a reader to conclude otherwise.

If your research program involves animal models, the relevant expertise sits with a licensed veterinarian and your institution's animal care and use committee — talk to your veterinarian before any in vivo work, because that guidance is theirs to give and not a supplier's. And if part of your business is clinical or licensed in any way, the questions worth raising with counsel are structural ones: what does resale of research-use-only material require under your state's framework, how must it be labelled and recorded, and what does your professional board expect of a licensee who also operates a product business? Those answers vary, they change, and they are not something a supplier's blog can settle. This article is informational and is not legal advice — bring the specifics to your attorney and your state board.

What Real Peptides does differently

Real Peptides built its Wholesale Partner Program around removing the two frictions above — unverifiable testing and opaque pricing.

Every compound in the catalog is tested to 99%+ HPLC purity and put through seven-panel batch testing, and the resulting certificates of analysis are published where any buyer can read them before ordering. That last point is the one that matters most in practice: a prospective partner can pull up the lab results for a specific lot, inspect the chromatogram, and make a sourcing decision on evidence rather than on a claim in a sales email. Test data isn't an upsell and isn't withheld pending a signed agreement.

Fulfillment is domestic, with orders shipping in 5–7 days from within the US — no customs exposure, no indefinite transit windows on inventory you've already promised to a customer. Onboarding runs through a three-step wholesale application: submit your business details, get reviewed for program eligibility, and receive partner pricing on approval. Wholesale rates scale with volume rather than with negotiating leverage, so what you see is what your competitors with the same order profile see.

What the program does not do is stock the compounds that generate the most inbound requests and the most legal exposure. Semaglutide, tirzepatide, retatrutide, and Melanotan II are not part of the catalog, and any supplier offering them wholesale should prompt questions about the rest of their operation. Supplies such as bacteriostatic water and syringes are likewise not bundled with compounds — research chemicals are sold as research chemicals, not as kits.

Building depth around the GH-axis category

Buyers who stock a short-acting GHRH analog usually end up building out the surrounding research categories too, because that's where their customers' interests cluster. Ipamorelin 10mg and Tesamorelin 10mg sit in the same signaling literature and are commonly catalogued alongside it, while compounds like MOTS-c 10mg, AOD-9604, and 5-Amino-1MQ are studied in metabolic-pathway contexts that overlap with the same research questions. Listing them as distinct compounds with distinct documentation — rather than as a themed bundle — keeps your catalog defensible and easier for a researcher to navigate.

If you're evaluating suppliers for a GHRH-analog line, the sequence is simple: read the published COA for the exact lot, confirm net peptide content and salt form, check that the no-DAC designation is unambiguous, and confirm domestic fulfillment timing against your own inventory cycle. If Real Peptides clears those checks for your catalog, the Wholesale Partner Program application at realpeptides.co is the next step, and approved partners get volume-based pricing without a negotiation cycle.

For broader category context, the Growth Factor & Tissue Signaling Research and Mitochondrial & Metabolic Pathway Research collections group related compounds by research area, and the Popular Peptides collection shows what moves most across the partner base — each with its batch documentation attached.